Segments (Tables)

3 Months Ended

Mar. 31, 2022

Segment Reporting [Abstract]

Operations and Assets for Operating Segments and Geographic Information

Information regarding our operations and assets for our operating segments and the unallocated corporate operations as well as geographic information are as follows:

	For the three months ended March 31,
(In thousands)	2022		2021
Revenue from services:
Pharmaceutical	$	—	$	—
Diagnostics	286,599		506,951
Corporate	—		—
	$	286,599	$	506,951
Revenue from products:
Pharmaceutical	$	36,658	$	33,945
Diagnostics	—		—
Corporate	—		—
	$	36,658	$	33,945
Revenue from transfer of intellectual property and other:
Pharmaceutical	$	5,962	$	4,269
Diagnostics	—		—
Corporate	—		—
	$	5,962	$	4,269
Operating income (loss):
Pharmaceutical	$	(18,108)	$	(19,157)
Diagnostics	(43,548)		67,014
Corporate	(10,768)		(9,420)
	$	(72,424)	$	38,437
Depreciation and amortization:
Pharmaceutical	$	15,402	$	7,413
Diagnostics	12,412		12,576
Corporate	—		—
	$	27,814	$	19,989
Loss from investment in investees:
Pharmaceutical	$	(49)	$	(43)
Diagnostics	—		—
Corporate	—		—
	$	(49)	$	(43)
Revenues:
United States	$	291,808	$	512,871
Ireland	8,462		7,129
Chile	16,339		14,152
Spain	7,109		5,919
Israel	1,558		2,512
Mexico	3,750		2,418
Other	193		164
	$	329,219	$	545,165

(In thousands)	March 31, 2022		December 31, 2021
Assets:
Pharmaceutical	$	1,099,633	$	1,114,460
Diagnostics	1,152,173		1,238,583
Corporate	55,052		46,672
	$	2,306,858	$	2,399,715
Goodwill:
Pharmaceutical	$	236,028	$	237,576
Diagnostics	283,024		283,025
	$	519,052	$	520,601